CLINICAL TRIAL REVIEW

chain reaction on previously biopsied skin specimens and newly biopsied skin specimens to evaluate the expression of various angiogenic factors in these dermatologic diseases.In addition, some of the skin specimens may be used to make cell cultures to study expression of angiogenic factors and interactions of cells in dermatologic disease. Additionally, the researchers can use discarded human skin tissue samples from skin biopsy/surgery sites that are removed for closure but not submitted for histopathologic analysis.Specimens collected will be processed for microarray analysis, qPCR, and/or immunohistochemistry to evaluate expression of various angiogenic factors and their receptors, including but not limited to: vascular endothelial growth factor, basic fibroblast growth factor, angiopoietin 1, angiopoietin 2, and matrix metalloproteinase.

The purpose of this study is to see how many patients develop hair, skin, and nail changes due to cancer treatments. The investigators will study the clinical factors, genetic markers, and impact on patients' health-related quality of life (HRQoL) to learn more about who is at greater risk. The study is intended to improve understanding of how cancer patients feel about their skin, hair, and nail conditions. This information will helpthe researchers determine the burden on breast cancer patients and survivors. It will also help them to learn how to prevent these conditions, and it may improve the way they treat them and counsel patients.Patients will undergo study related assessments and the appropriate HRQoL questionnaires will be administered. Baseline and follow-up clinical assessments will be performed, preferably when the patient presents to the clinic for (clinically indicated) standard-of-care visits. Initially, these visits will be coinciding with the appropriate chemotherapy dosing cycles (as applicable to select study cohorts), and subsequently they will be performed during the standard-of-care follow-up visits.